drugset / Trial / NCT03050476

Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase

NCT03050476 ↗

Phase 2/3 Unknown 1250 enrolled Alloksys Life Sciences B.V. Aix Scientifics · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Study should demonstrate that alkaline phosphatase reduces the incidence and extent of acute kidney injury after cardiopulmonary bypass (CPB) as defined by the AKIN criteria.

Timeline

Start
2017-11-01
Primary completion
2025-09-30
Completion
2026-03-31

Outcome

Missed primary endpoint

release “While these endpoints were not found for the total patient cohort in this phase IIb trial” alloksys.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject RESCAP® Unknown 10000 iu Intravenous